Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
about
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyRelevance of tumor-infiltrating lymphocytes in breast cancerAntibody-based immunotherapy of solid cancers: progress and possibilitiesCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyMinireview: Regulatory T Cells and Ovarian Cancer.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Immune checkpoint inhibitors in clinical trialsEngineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imagingEnhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection.Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpointImmune based therapy for melanomaAgonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Mechanism of immune evasion in breast cancer.Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology?Checkpoint inhibitors in immunotherapy of ovarian cancer.Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.Programmed death-1 & its ligands: promising targets for cancer immunotherapy.Emerging immune checkpoints for cancer therapy.Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Immune checkpoint inhibition in ovarian cancer.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cellsModulation of tumor immunity: a patent evaluation of WO2015026684A1.Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice.Anti-GITR therapy promotes immunity against malignant glioma in a murine model.The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.Next generation immune-checkpoints for cancer therapy.The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer
P2860
Q26783783-D01FABF6-A026-4AF1-8C24-5AB4C65E3AABQ26795598-9DE2224E-E112-4F9D-B7F2-BB7470DD8948Q26796542-9D709BFB-F1F7-4EB7-A01C-8DAF4337DB06Q28066199-FD0FC239-3EDF-4820-80B6-B9567EB6A71AQ30244214-C75E40F7-7E06-4BB3-AA15-FF1F625ECEEFQ33889105-D74D6885-C5FC-4F50-A8DB-4B6953B73B11Q34309394-4A08E331-E98C-4270-A6FC-4DEB21CB7CC8Q34502985-3D764CD7-18E2-4BAC-BF04-67C1363897D1Q35147454-98113B2B-111B-47A4-94B1-B5A8D8FD10C0Q35896426-DF794F08-3D7D-4E21-ADC8-FFCAEFBF5985Q36024656-151E9925-611B-42CF-8555-56DE1666503BQ36360125-2EBAC266-B945-4B62-8F41-523A650B0128Q36875531-979E34DB-09CA-46B4-8BC2-EA87E47D23C2Q36876757-C60F3C56-5980-4D88-9FC3-08E10FEB1E01Q36907372-EE78EE66-CA24-49AA-B083-145439E1231CQ37158481-DE2E83DA-DB70-4B8A-9C26-F79F22855632Q37712385-95746F70-5679-49F2-97EC-C5AD4BB67FD7Q38225334-A23EC45F-32AC-4C84-A75F-1D26823A38B9Q38269568-4E0F629F-21EB-4766-8255-FD5B6FC7BB8DQ38548339-3C5D3E7D-541F-4235-83EC-130556D12198Q38562062-4AB9AEAF-4B8B-492E-8F93-A7E4089E0AD1Q38584979-3C8BB3C3-E6B9-4FB0-8E4A-A2A0FD95F61FQ38621228-6FEA59A2-8CE8-4121-AB81-AB8EF227019FQ38636430-846CE468-4B3A-42A4-A07B-6DD3D255CFA3Q38666253-22B6BDB2-D232-48F8-9D35-9AEF74B433C2Q38770458-F3A54DAB-7411-4A09-8CBA-EB4829BD7281Q38770814-11C37EB4-7AAF-42C8-BEFC-24713AA59EE8Q38800974-3FCDFB68-3E36-4FD3-992F-16498FB19C7EQ38806038-24D6551B-790E-439D-9877-12CDD62D3200Q38838643-668B688E-BC63-45B8-A110-A2F6D793574BQ39402079-72650D91-5821-4ABD-82A6-70BC4C28066AQ40517920-6A570F54-2CDB-4D6E-B79E-1D81FBF3817BQ41557983-62206081-6D05-4297-A1DC-742950565EADQ41701367-33119C58-5998-4ED8-98BF-18DE321EAD8BQ46640448-588FBBA0-BA32-4C3E-A950-48DAD646C128Q48228066-B9141D9E-08CA-4C91-8CDA-E51887F96C83Q48480477-92837167-037A-4000-9786-330DEB5F9B5BQ54980315-30854285-3A65-48F3-A788-761066881299Q55383705-658DDD2D-40B8-4F78-A58C-A96F0DF39B45Q57114285-E3757405-F096-41CF-A859-8502E052A9D5
P2860
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@ast
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@en
type
label
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@ast
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@en
prefLabel
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@ast
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@en
P2093
P2860
P356
P1476
Combined PD-1 blockade and GIT ...... s with chemotherapeutic drugs.
@en
P2093
Hongzan Ji
Rongsheng Zhang
Xiaobing Xu
P2860
P2888
P356
10.1186/1479-5876-12-36
P577
2014-02-07T00:00:00Z
P5875
P6179
1031646629